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Summary
Left ventricular assist systems (LVAS) are widely accepted nowadays as a 
successful tool for bridging the patients with end-stage heart failure to heart 
transplantation (BTT). The second generations of axial-flow devices, such as the 
HeartMate II, provide a safe and reliable, as well as an effective hemodynamic 
support in such patients, offering them an improved quality of life; they are 
furthermore associated with a very low rate of device malfunction or infection 
requiring device change. We report here of our first three patients with the im-
planted HM II LVAS as a BTT.
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Introduction
Currently, approximately 14 million people in Europe suffer from heart failure; 
this number is forecast to increase to 30 million by the year 2020 and is associated 
with high mortality and morbidity rates [1,2]. Nearly 40 % of heart failure patients will 
die within one year of their first hospitalization, whilst only 25 % of men and 38 % of 
women will survive more than five years following the diagnosis [2]. Heart transplan-
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tation is still the most successful treatment option for patients with advanced heart 
failure refractory to medical therapy. The REMATCH (Randomized Evaluation of Me-
chanical Assistance for the Treatment of Congestive Heart Failure) trail demonstrated 
a survival advantage for the left ventricular assist devices (LVADs) therapy over opti-
mal medical management for patients with advanced heart failure, who were not eli-
gible for transplantation [3]. LVADs are nowadays widely accepted as a successful tool 
for bridging the patients with end-stage heart failure to heart transplantation (BTT) 
[4]. As a consequence of limited donor availability, waiting lists for heart transplan-
tation (HTx) are growing as are support durations for VADs in BTT programmes [5]. 
Although the first generation of pulsatile devices have shown good results as BTT de-
vice, they are – to a certain extent – limited in their design and mechanical durability. 
These limitations include a large pump size; the need for extensive surgical dissection 
for implant; a larger body habitus of the recipient; and audible pump operation [5,6]. 
The second generation of smaller axial-flow devices that produce a continuous flow, 
such as the HeartMate II (HM II), provide a safe and reliable, as well as an effective 
hemodynamic support in patients awaiting transplantation, with improved quality of 
life, and are associated with a very low rate of device malfunction or infection requi-
ring device exchange.7 In this paper, we report our first three patients with implanted 
HM II left ventricular assist system (LVAS) as a BTT. 
The description of HeartMate II Left Ventricular Assist System
HeartMate II LVAS (Thoratec Corporation; Pleasanton, California) is an axial-
flow rotary ventricular assist system composed of a blood pump, a percutaneous 
lead, an external power source and a system driver with a spinning motor as its 
only moving part (Fig. 1). The HM II has an electromagnetic motor contained in the 
pump housing and creates a magnetic field that spins the rotor and imports torque 
to its internal bladed impeller. No compliance chamber or valves are necessary, and 
a single driveline exits the right lower quadrant of the abdomen. The inlet cannula 
is placed in the apex of the left ventricle, and the outflow cannula is anastomosed to 
the ascending aorta. The small, 124 mL LVAS greatly reduces the amount of dissec-
tion required to crate a nesting pocket and is placed intraperitoneally or extraperi-
toneally. The pump is designed to spin at 6,000 to 15,000 rotations per minute and to 
produce as much as 10 L/min of cardiac output. 
The surgical procedure
We are describing the standard operative protocol that was – with a few dif-
ferences – used in all three patient cases. A median sternotomy was performed, 
and a cardiopulmonary bypass (CPB) was instituted. The inflow cannula was first 
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placed in the left ventricular apex after apical coring. Sutures were used to secure 
the sewing ring to the ventricle under direct visualization. The inlet cannula was 
inserted into the swing ring and secured. The outflow graft was then anastomosed 
via outflow conduit to the ascending aorta in an end-to-side fashion, and the pump 
was activated. The pump was placed parallel to the diaphragm in a previously made 
pocket within the muscles of the abdominal wall. Following de-airing, the patient 
was weaned from the CPB in the usual fashion.
Case report 1
The first HeartMate II was implanted in a 59-year-old man with a history of 
ischemic cardiomyopathy, glucose intolerance and renal insufficiency. Four years 
prior to the operation, he underwent a triple coronary artery bypass grafting with 
the aneurysmoraphy of the left ventricle due to two myocardial infarctions. Six 
months before the operation, his condition started to deteriorate due to the global 
cardiac decompensation and the impairment of the renal function with the New 
York Heart Association functional class (NYHA) III/IV. A control echocardiogram 
revealed an ejection fraction around 0.20, with global hypokinesis. In addition, he 
had extremely dilated left ventricle, dilated atria and moderate mitral regurgitati-
Fig. 1: LVAS
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on. His estimated pulmonary artery pressure was 31 mmHg, pulmonary vascular 
resistance 1.57 wood units with an ejection fraction of the right ventricle 0.35. With 
aggressive conservative management, the patient was – prior to the operation – in 
NYHA class II with improved renal function and listed as a candidate for a heart 
transplant. In June 2009, he underwent the implantation of HeartMate II LVAS. Early 
after the operation, the patient was hemodynamically stable, however with a higher 
output on drainage tubes, which finally required a revision and hemostasis next 
morning. After the procedure, the patient was hemodynamically unstable on high-
dosage inotropic agents, unresponsive to vasopressors, and with a progression to 
low cardiac output syndrome. Subsequently, he became rhythmically unstable and 
developed ventricular fibrillation, which could not be converted after multiple defi-
brillation and medication support. He transesophageal echocardiography revealed 
the akinesia of the right ventricle, with severe tricuspid regurgitation. The patient 
eventually succumbed to multi-organ failure on the 2nd postoperative day due to 
acutely developed right-heart failure. The autopsy revealed an acute myocardial in-
farction of the right ventricle.
Case report 2
The second HeartMate II was implanted in a 57-year-old woman with a history 
of dilated cardiomyopathy of unknown cause, which was diagnosed 10 years ear-
lier. Within the last year, she was on several occasions admitted to hospital due to 
cardiac decompensation and minimal tolerance to any physical activity. The echo-
cardiogram revealed an extremely dilated and hypokinetic left ventricle with ejec-
tion fraction 0.15, and severe mitral regurgitation. Her estimated pulmonary artery 
pressure was 45 mmHg, and her pulmonary vascular resistance was 2.7 wood units. 
Her right ventricle was moderately dilated with ejection fraction 0.35. The patient 
was listed for a heart transplant and was recognized as a candidate for HM II LVAS 
that was implanted in October 2009. The initial postoperative transthoracic echo-
cardiogram revealed that the aortic valve was opening with lower pump speeds, 
so the pump rate was maintained at 9,500 rpm. The histological examination of the 
myocardial plug revealed myocyte hypertrophy, clusters of lipofuscin pigment wit-
hout any sign of myocarditis. Early postoperatively, there was occurrence of gastro-
intestinal bleeding that was treated with endoscopical coagulation without further 
complications. We also noticed local infection around the percutaneous lead, with 
positive strains of Corynebacterium spp and Staphylococcus aureus; the infection was 
successfully treated with systemic antibiotics and aggressive wound care. On seve-
ral consecutively preformed transthoracic echocardiographies, the ejection fraction 
of the left ventricle was around 0.40 with normal position and flow of inlet cannu-
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la, paradoxical septal motion and moderate to severe tricuspid regurgitation. The 
anticoagulation treatment was started by intravenous heparin until we achieved 
international normalized ratio 2.5 – 3.5 with oral warfarin. The patient was given 
aspirin as well. No other significant clinical events occurred during the postopera-
tive period, and she begun an aerobic exercise programme approximately 1 week 
following the operation. During the hospital stay, HM II was functioning properly, 
and the patient was a month and a half after the operation sent home. (Fig. 2) She 
remains in NYHA class I with no symptoms and is awaiting the transplantation 
more than 4 months after the implantation.
Fig. 2: Our patient with HM II
Case report 3
A 62-year-old woman with a history of hypertension, hyperlipidemia, diabetes 
and smoking also suffered an ischemic stroke 20 years ago, which was resolved 
completely. Two months prior to the implantation of HeartMate II LVAS, she was 
admitted to our hospital because of cardiac decompensation due to dilated cardi-
omyopathy of unknown cause. At that time, transthoracic echocardiography was 
used to reveal ejection fraction of the left ventricle around 0.20, with severe mi-
tral regurgitation, without any apparent sign of pulmonary hypertension. A month 
before the implantation procedure, she was repeatedly hospitalized due to global 
heart decompensation and NYHA class III-IV. Despite optimal medical therapy, 
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the patient’s clinical state started to deteriorate, and she had symptoms even while 
resting and with minimum exertion. In February 2010, she underwent the implan-
tation of HeartMate II LVAS. Early after the operation, the patient was hemodyna-
mically stable, the initial echocardiogram revealed occasional opening of the aortic 
valve, good position of the inflow cannula within the dyskinetic septum. Additio-
nal studies approximately three weeks after implantation revealed that the optimal 
pump speed was 8,800 rpm (4,4 L/min), which has been maintained since then. The 
patient was discharged home 4 weeks after the implantation. No adverse clinical 
events have occurred so far.
Discussion
A main therapeutic goal in treating patients with advanced heart failure is to 
enhance their quality of life and functional capabilities. Several studies showed that 
the implantation of a continuous-flow left ventricular assist device, as compared to 
pulsatile-flow device, has significantly improved the probability of survival free of 
stroke and reoperation due to device malfunction in patients with advanced heart 
failure, in whose cases the current therapy had failed, and who were ineligible for 
transplantation [3,8].  The continuous flow devices, such as HM II, are smaller than 
the previous ones and have fewer mobile parts, thereby increasing their mecha-
nical durability. Regarding adverse events, according to Laphor et al., the bleeding 
remains a serious problem with incidences of more than 50 %, as are infectious 
complications of the drive-line, as noticed in our patient group, which – when well 
treated – are not life-threatening [9]. Therefore, the authors suggest a less aggressive 
anticoagulation protocol in view of a common absence of pump thrombosis. They 
also concluded that the HM II, while used for BTT, might also be used for destina-
tion therapy. We have presented the first three patients in Croatia to be supported 
with HM II as a bridge-to-transplant. One patient succumbed an acutely developed 
right heart failure, whilst the other two were, without any complications, more than 
4 and 1 month post-implant respectively, successfully rehabilitated. 
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Sažetak
Rana klinička iskustva sa dugoročnom potporom (Heart Mate II)
Uređaji za potporu lijevom srcu (LVAS – left ventricular assist system) su danas prihvaćeni 
kao uspiješno sredstvo za premoštenje bolesnika u završnom stadiju zatajivanja srca do tran-
splantacije. Druga generacija aksijalnih pumpi, kao što je HeartMate II, pruža sigurnu i učinko-
vitu hemodinamsku potporu takvim bolesnicima, poboljšavajući kvalitetu života. Danas su ti 
uređaji povezani sa niskom inicidencijom malfunkcije ili infekcije koje bi zahtijevale zamjenu. 
Prikazujemo naša tri bolesnika kojima je ugrađen HeartMate II LVAS kao premoštenje do tran-
splantacije. 
Ključne riječi: HeartMate II LVAS; premoštenje do transplantacije; zatajivanje srca

